Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE LA 120 50 versus METOPROLOL TARTRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERIDE LA 120 50 versus METOPROLOL TARTRATE.
INDERIDE LA 120/50 vs METOPROLOL TARTRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propranolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium reabsorption and promoting diuresis.
Competitive beta-1 adrenergic receptor antagonist with weak beta-2 blocking activity; reduces heart rate, contractility, and AV conduction.
One capsule orally once daily, containing 120 mg propranolol HCl and 50 mg hydrochlorothiazide.
Initial dose 100 mg daily in divided doses (e.g., 50 mg twice daily) orally; may increase weekly up to 200-450 mg daily in 2-3 divided doses.
None Documented
None Documented
Propranolol: 3-6 hours; Hydrochlorothiazide: 6-15 hours. Note: Inderide LA is an extended-release formulation; effective half-life extended to approximately 8-12 hours for propranolol component.
3–4 hours (terminal) in healthy adults; prolonged to 7–8 hours in severe hepatic impairment; no change in renal impairment.
Primarily hepatic metabolism (90%+), with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for negligible amounts.
Renal: 95% as metabolites, <5% unchanged. Fecal: negligible.
Category C
Category C
Beta-Blocker/Diuretic Combination
Beta-Blocker